Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770948 | 1.00 | PPARA (0.47) | PPARAPPARGMAPK1EGLN2PPARD | |
| SCHEMBL1770705 | 0.90 | MAPK1 (0.43) | PPARAPPARGMAPK1KDM4ENPC1 | |
| SCHEMBL1770707 | 0.90 | MAPK1 (0.43) | PPARAPPARGMAPK1KDM4ENPC1 | |
| SCHEMBL1770918 | 0.83 | F10 (0.48) | F10 | |
| SCHEMBL20560085 | 0.82 | F10 (0.53) | MAPK1LMNAF10 | |
| SCHEMBL1770395 | 0.82 | F10 (0.53) | MAPK1LMNAF10 | |
| SCHEMBL5626363 | 0.80 | ITGB3 (0.63) | PPARAPPARGEGLN2ITGB3ITGA2B | |
| SCHEMBL5626356 | 0.80 | ITGB3 (0.63) | PPARAPPARGEGLN2ITGB3ITGA2B | |
| SCHEMBL1771149 | 0.78 | PPARA (0.43) | PPARAPPARGEGLN2PPARDACE | |
| SCHEMBL1771151 | 0.78 | PPARA (0.43) | PPARAPPARGEGLN2PPARDACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637479-B2 | Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide | SANOFI (FR) | 2017-05-02 | — | — | US | disclosed |
| US-9637479-B2 | Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide | SANOFI (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160102082-A1 | TARTRATE SALT OF 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID [(S)-2-[METHYL-3-(2-OXO-PYRROLIDIN-1-YL)-BENZENESULFONYLAMINO]-3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPYL]AMIDE | BEIJING COLLAB PHARM CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| US-8378092-B2 | Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin | SANOFI (FR) | 2013-02-19 | — | — | US | disclosed |
| EP-2254881-B1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | SANOFI SA (FR) | 2012-09-12 | — | — | EP | disclosed |
| US-20110112075-A1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102082-A1 | TARTRATE SALT OF 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID [(S)-2-[METHYL-3-(2-OXO-PYRROLIDIN-1-YL)-BENZENESULFONYLAMINO]-3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPYL]AMIDE | CPS1, ACP3, ACP1 | PPARA 88/4885PPARG 154/4885MAPK1 2423/4885 |
| US-20110112075-A1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | F12, F3, F2 | PPARA 3722/4885PPARG 3634/4885MAPK1 3632/4885 |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | PPARA 3274/4885PPARG 2913/4885MAPK1 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.